Inhibition of GSK-3β may inhibit tumor growth and improve survival through several complimentary mechanisms that include enhancement of chemotherapy activity, activation of innate anti-tumor immunity, ...

University at Buffalo researchers shed some light on an enduring neuroscience mystery: How exactly does a mutated huntingtin ...

Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

Tda1 protein kinase, activated by Snf1 and yeast GSK3-β, fine-tunes metabolism through the phosphorylation of Hxk2, which is ...

difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that topline clinical data from the randomized Phase 2 study (Actuate-1801 Part 3B) ...

Users installing the latest beta will receive the latest fixes and optimizations first, and will be able to submit feedback via an app installed within the build itself. The Android Developers ...

"Elraglusib with chemotherapy and immune priming represents a novel sequential therapy approach to treat advanced salivary cancers. We were encouraged by the response rate among the non-Adenoid ...

Amidst this, BlockDAG (BDAG) is progressing swiftly. Its recent Keynote 3 announcement confirmed the Beta Testnet V1 is operational and open for public usage. Participants are actively testing tools, ...